Euthymics' Sweet Dreams Could Be Realized With $24MM Series A
This article was originally published in The Pink Sheet Daily
Executive Summary
The startup will resume trials on a novel antidepressant lost in the shuffle when DOV Pharmaceuticals ceased operations.